Management of Hepatocellular Carcinoma: Current Status and Future Directions

被引:46
作者
Au, Jennifer S. [1 ]
Frenette, Catherine T. [2 ]
机构
[1] Scripps Clin, Div Gastroenterol & Hepatol, La Jolla, CA 92037 USA
[2] Scripps Clin, Liver Transplantat, Ctr Organ & Cell Transplantat, La Jolla, CA 92037 USA
关键词
Carcinoma; hepatocellular; Transarterial chemoembolization; Radiofrequency ablation; Staging systems; Sorafenib; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; ORTHOTOPIC LIVER-TRANSPLANTATION; RADIOFREQUENCY THERMAL ABLATION; UNIVERSITY PROGNOSTIC INDEX; RANDOMIZED CONTROLLED-TRIAL; DOXORUBICIN-ELUTING BEADS; LONG-TERM SURVIVAL; TRANSARTERIAL CHEMOEMBOLIZATION; RADIATION-THERAPY; ETHANOL INJECTION;
D O I
10.5009/gnl15022
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatocellular carcinoma (HCC) is the second most common cause of cancer death worldwide. This cancer commonly arises against a background of chronic liver disease. As a result, a patient with HCC requires multidisciplinary care. Treatment options vary widely based on tumor burden and metastases. The most widely utilized staging system. is the Barcelona Clinic Liver Cancer staging system, which recommends treatments based on tumor size and the underlying liver disease and functional status of the patient Treatment options range from surgical resection or transplantation to locoregional therapies with modalities such as radiofrequency ablation and transarterial chemoembolization to systemic chemotherapies. Future care involves the development of combination therapies that afford the best tumor response, further clarification of the patients best suited for therapies and the development of new oral chemotherapeutic agents.
引用
收藏
页码:437 / 448
页数:12
相关论文
共 120 条
[1]   Retreatment with TACE: The ABCR SCORE, an aid to the decision-making process [J].
Adhoute, Xavier ;
Penaranda, Guillaume ;
Naude, Sebastien ;
Raoul, Jean Luc ;
Perrier, Herve ;
Bayle, Olivier ;
Monnet, Olivier ;
Beaurain, Patrick ;
Bazin, Christophe ;
Pol, Bernard ;
Le Folgoc, Gaelle ;
Castellani, Paul ;
Bronowicki, Jean Pierre ;
Bourliere, Marc .
JOURNAL OF HEPATOLOGY, 2015, 62 (04) :855-862
[2]  
[Anonymous], 2012, EST CANC INC MORT PR
[3]  
[Anonymous], 2014, Cancer Facts and Figures 2014
[4]   Development of Tivantinib as Treatment for Hepatocellular Carcinoma [J].
Au, Jennifer ;
Frenette, Catherine .
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2013, 1 (01) :75-78
[5]   Opinion -: Invasive growth:: a MET-driven genetic programme for cancer and stem cells [J].
Boccaccio, Carla ;
Comoglio, Paolo M. .
NATURE REVIEWS CANCER, 2006, 6 (08) :637-645
[6]   Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions [J].
Bolondi, Luigi ;
Burroughs, Andrew ;
Dufour, Jean-Francois ;
Galle, Peter R. ;
Mazzaferro, Vincenzo ;
Piscaglia, Fabio ;
Raoul, Jean Luc ;
Sangro, Bruno .
SEMINARS IN LIVER DISEASE, 2012, 32 (04) :348-359
[7]   Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis [J].
Breitenstein, S. ;
Dimitroulis, D. ;
Petrowsky, H. ;
Puhan, M. A. ;
Muellhaupt, B. ;
Clavien, P. -A. .
BRITISH JOURNAL OF SURGERY, 2009, 96 (09) :975-981
[8]   Chemoembolization for hepatocellular carcinoma [J].
Bruix, J ;
Sala, M ;
Llovet, JM .
GASTROENTEROLOGY, 2004, 127 (05) :S179-S188
[9]   Management of hepatoceullular carcinoma [J].
Bruix, J ;
Sherman, M .
HEPATOLOGY, 2005, 42 (05) :1208-1236
[10]   ORTHOTOPIC LIVER-TRANSPLANTATION - 1ST 60 PATIENTS [J].
CALNE, RY ;
WILLIAMS, R .
BMJ-BRITISH MEDICAL JOURNAL, 1977, 1 (6059) :471-476